Form 4 for IMNM Immunome Inc.
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-22 · accession 0001808343-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-12-23 | 2025-12-22 | IMNM | Barchas Isaac | Dir | S - Sale | $21.74 | -383.2K | 2.03M | -16% | -$8.33M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-22 | S | D | 371,949 | $21.72 | 2,042,432 | I See footnotes | — | — | (F2) The shares were sold as follows: 226,480 shares were sold by Arsenal Bridge Venture II, LLC ("ABV II") and 145,469 shares were sold by Arsenal Bridge Venture II-B, LLC ("ABV II-B" and collectively with ABV II, the "ABV Entities"). (F3) The weighted average sale price for the transaction report was $21.72, and the range of prices were between $21.31 and $22.30, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F4) Following this transaction, ABV II and ABV II-B own 1,245,133 shares of Issuer common stock and 797,299 shares of Issuer common stock, respectively. (F5) Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares. |
| 2 | Common | Common Stock | 2025-12-22 | S | D | 11,251 | $22.34 | 2,031,181 | I See footnote | — | — | (F6) The shares were sold as follows: 6,851 shares were sold by ABV II and 4,400 shares were sold by ABV II-B. (F7) The weighted average sale price for the transaction report was $22.34, and the range of prices were between $22.31 and $22.38, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F8) Following this transaction, ABV II and ABV II-B own 1,238,282 shares of Issuer common stock and 792,899 shares of Issuer common stock, respectively. (F5) Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares. |